Inflarx Nv Stock Investor Sentiment

IFRX Stock  USD 2.33  0.22  8.63%   
Slightly above 60% of InflaRx NV's investor base is looking to short. The analysis of the overall investor sentiment regarding InflaRx NV suggests that many traders are alarmed. InflaRx NV's investing sentiment can be driven by a variety of factors including economic data, InflaRx NV's earnings reports, geopolitical events, and overall market trends.
  

InflaRx NV Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards InflaRx NV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a month ago at news.google.com         
Generation Bio Co. Reports Q3 2024 Financials and Progress - TipRanks
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Yahoo News
few days ago at thelincolnianonline.com         
Generation Bio Announces Executive Departures and Appointments
news
over three weeks ago at insidermonkey.com         
Kronos Worldwide Inc. The Small Cap Chemical Stock Hedge Funds Are Watching Closely
insidermonkey News
over a month ago at thelincolnianonline.com         
Kronos Worldwide Shares Gap Down Heres Why
news
over a month ago at investing.com         
Kronos Bio shares downgraded to hold by TD Cowen
Investing News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Charles Lin of 72900 shares of Kronos Bio at 0.96 subject to Rule 16b-3
Macroaxis News
over a month ago at aol.com         
Taylor Swift Eras Tour ends 8 moments that left fans shocked
news
over a month ago at zacks.com         
Erasca May Find a Bottom Soon, Heres Why You Should Buy the Stock Now
zacks News
over three weeks ago at forbes.com         
Taylor Swifts Eras Tour Was A Marvel And A Lesson In Personal Branding
Usa forbes News
over two months ago at finance.yahoo.com         
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
Yahoo News
over a month ago at news.google.com         
Stephens Initiates Coverage on C4 Therapeutics - MarketBeat
Google News at Macroaxis
over three weeks ago at zacks.com         
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
zacks News
3 days ago at businesswire.com         
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13,...
businesswire News
over a month ago at thelincolnianonline.com         
Polar Asset Management Partners Inc. Has 4.21 Million Stock Holdings in Edgewise Therapeutics, Inc.
news
over a month ago at thewest.com.au         
Kalamazoo a step closer to 30m payday after big drill results
news
over a month ago at news.google.com         
Kezar Life Sciences Given New 11.00 Price Target at Wells Fargo Company - MarketBeat
Google News at Macroaxis
over two months ago at businesswire.com         
Glancy Prongay Murray LLP Announces Investigation of Kezar Life Sciences, Inc.
businesswire News
over two months ago at australianmining.com.au         
De Grey makes headway at Ashburton
news
over two weeks ago at finance.yahoo.com         
Fulcrum Therapeutics shareholders have endured a 77 percent loss from investing in the stock three y...
Yahoo News
over a month ago at news.google.com         
Brokerages Set Fulcrum Therapeutics, Inc. Price Target at 9.33 - MarketBeat
Google News at Macroaxis
over two months ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in Fulcrum Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Lynx1 Capital Management Lp of 167055 shares of Passage Bio at 0.7075 subject to Rule...
Macroaxis News
over two months ago at finance.yahoo.com         
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Soc...
Yahoo News
six days ago at www.macroaxis.com         
Disposition of 10859 shares by Siemers Eric of Acumen Pharmaceuticals at 1.8461 subject to Rule 16b-...
Macroaxis News
over a month ago at simplywall.st         
I-Mab Leads Our Spotlight On 3 US Penny Stocks
Simply Wall St News at Macroaxis
over two months ago at globenewswire.com         
Insider Trading
Macroaxis News: globenewswire.com
2 days ago at news.google.com         
Acumen Pharmaceuticals chief legal officer sells 20,505 in stock By Investing.com - Investing.com Au...
Google News at Macroaxis
over two months ago at news.google.com         
Inozyme Pharmas Buy Rating Reaffirmed at Needham Company LLC - MarketBeat
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
Inozyme Pharma, Inc. Shares Bought by Eventide Asset Management LLC
news
over a month ago at gurufocus.com         
Eventide Asset Managements Strategic Acquisition of Inozyme Pharma Shares
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Gros David-alexandre C of 1015743 shares of Eledon Pharmaceuticals at 2.3 subject to ...
Macroaxis News
over a month ago at finance.yahoo.com         
Eledon Pharmaceuticals, Inc.s market cap dropped US48m last week individual investors who hold 57 pe...
Yahoo News
over two months ago at globenewswire.com         
Acquisition by Bvf Partners L Pil of 440489 shares of Eledon Pharmaceuticals at 0.001 subject to Rul...
Macroaxis News: globenewswire.com
3 days ago at news.google.com         
Eledon Pharmaceuticals Trading Down 3.9 percent - Should You Sell - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
Icosavax Corporate Overview - Marketscreener.com
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stoc...
Yahoo News
over two weeks ago at news.google.com         
Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance
Google News at Macroaxis
over a month ago at finance.yahoo.com         
RVPH Year-End OLE Update
Yahoo News
over two months ago at globenewswire.com         
Reviva to Participate in the UBS Global Healthcare Conference
Macroaxis News: globenewswire.com
2 days ago at finance.yahoo.com         
US Penny Stocks Arbe Robotics And 2 More Promising Picks
Yahoo News
over a month ago at news.google.com         
Earnings Outlook For Protalix BioTherapeutics - Benzinga
Google News at Macroaxis
over a month ago at gurufocus.com         
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635
Gurufocus Stories at Macroaxis
over a month ago at globenewswire.com         
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for ...
Macroaxis News: globenewswire.com
over two months ago at finance.yahoo.com         
EyePoint Pharmaceuticals Q3 Earnings Snapshot
Yahoo News
over two weeks ago at thelincolnianonline.com         
Standard Life UK Smaller Companies Trust Shares Cross Below 200-Day Moving Average Time to Sell?
news
over a month ago at globenewswire.com         
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of ...
Macroaxis News: globenewswire.com
over two months ago at gurufocus.com         
Highbridge Capital Managements Strategic Acquisition of SELLAS Life Sciences Shares
Gurufocus Stories at Macroaxis
over a month ago at zacks.com         
Wall Street Analysts See a 64.09 percent Upside in Monte Rosa Therapeutics Can the Stock Really Move...
zacks News
over three weeks ago at finance.yahoo.com         
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and...
Yahoo News
over two months ago at seekingalpha.com         
Monte Rosa Therapeutics GAAP EPS of -0.29
seekingalpha News
3 days ago at news.google.com         
Solid Biosciences stock jumps 11 percent post-market on FDA update - MSN
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Insider Sell Alert Deepa Prasad Sells Shares of Design Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Werewolf Therapeutics, Inc. Short Interest Update
news
over a month ago at investing.com         
Werewolf Therapeutics SWOT analysis oncology biotechs stock potential amid clinical progress
Investing News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Daniel Hicklin of 295500 shares of Werewolf Therapeutics subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Ikena Oncologys Neutral Rating Reaffirmed at Wedbush
news
over three weeks ago at www.macroaxis.com         
Disposition of 11989 shares by Atlas Venture Fund Xi, L.p. of Ikena Oncology at 15.03 subject to Rul...
Macroaxis News
over a month ago at news.google.com         
Ikena Oncology FY2024 EPS Forecast Lifted by HC Wainwright - MarketBeat
Google News at Macroaxis
2 days ago at bizjournals.com         
How former leaders of a sold-off biotech company landed their drugs again
bizjournals News
over a week ago at www.macroaxis.com         
Acquisition by Kaye Edward M. Md of 35000 shares of Stoke Therapeutics at 0.6 subject to Rule 16b-3
Macroaxis News
over a month ago at thelincolnianonline.com         
Disposition of 10000 shares by Ticho Barry of Stoke Therapeutics subject to Rule 16b-3
news
over a month ago at finance.yahoo.com         
Stoke Therapeutics Presents New Open-Label Extension Study Data That Further Support the Potential f...
Yahoo News
Far too much social signal, news, headlines, and media speculation about InflaRx NV that are available to investors today. That information is available publicly through InflaRx media outlets and privately through word of mouth or via InflaRx internal channels. However, regardless of the origin, that massive amount of InflaRx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of InflaRx NV news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of InflaRx NV relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to InflaRx NV's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive InflaRx NV alpha.

InflaRx NV Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
InflaRx Short Interest Update
10/14/2024
2
InflaRx N.V. Reports Q3 Loss, Tops Revenue Estimates
11/08/2024
3
Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential
11/19/2024
4
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
12/20/2024
5
InflaRx Announces Participation in January Events in San Francisco
01/07/2025

Additional Tools for InflaRx Stock Analysis

When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.